A novel urine test to monitor antiretroviral treatment efficacy in HIV patients

Optimising metabonomic analysis to monitor combination antiretroviral therapy efficacy in urine samples from HIV patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN10430191

Enrollment

Registered

2015-10-28

Start date

2015-10-01

Completion date

Unknown

Last updated

2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human immunodeficiency virus (HIV) Infections and Infestations Human immunodeficiency virus (HIV)

Interventions

Ten sequential samples are taken from each patient over the course of 10 weeks. The intra-patient variability is determined in the metabolic profiling of patients who are stable on ART with undetectab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. At least 18 years of age 2. HIV positive 3. Currently taking combination antiretroviral therapy 4. Two undetectable viral loads measured in the most recent visits

Exclusion criteria

Exclusion criteria: Persons who lack the capacity to consent

Design outcomes

Primary

Measure	Time frame
Urine metabonomic profiles will be measured using proton nuclear magnetic resonance spectroscopy and liquid chromatography mass spectrometry on days 1, 2, 3, 4, 5, 15, 29, 43, 57 and 71.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026